New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM

Press/Media: Press / Media

PeriodJun 5 2017 → Jun 7 2017

Media coverage

13

Media coverage

  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date6/7/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date6/6/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletTMC Net
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletTMC Net
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletBioSpace
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outlet4 Traders
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletStockwatch
    CountryCanada
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletCustomer Zone 360.com
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletIndia Pharma News
    CountryIndia
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletGlobeNewswire
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletDaily Times Leader
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletPrimeNewswire (Top News)
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner
  • TitleNew Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
    Media name/outletEIN News
    CountryUnited States
    Date6/5/17
    PersonsAndrew Brenner